A recent study finds that galantamine has a much lower mortality rate among patients with mild to moderately severe Alzheimer's disease compared to placebo. The findings were presented at the American College of Neuropsychopharmacology 51st Annual Meeting in Hollywood, and come from a study sponsored by Fla. Janssen Research & Development, LLC. Galantamine not only reduced mortality rates, but also slowed down declines in cognitive impairment over a 24-month period, compared to those who were given placebo...
More...
More...